Johnson & Johnson on Tuesday reported quarterly earnings and revenue that topped Wall Street’s expectations, and lifted its full-year guidance as sales in the company’s pharmaceutical and medical devices businesses surged.It marks J&J’s first quarterly results since it completed the separation from its consumer health spinoff Kenvue in August, the company’s biggest shake-up in its 137-year history.Upon that separation in August, J&J also lowered its full-year sales and profit guidance.The drugmaker raised that revised outlook on Tuesday: J&J expects 2023 sales of $83.6 billion to $84 billion,compared with previous guidance of $83.2 billion to $84 billion in August.

2023 Third-Quarter reported sales growth of 6.8% 到 $21.4 Billion with operational growth of 6.4% and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%.
Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%
Company is increasing 2023 full-year guidance midpoints for sales5 and adjusted EPS

Overall Financial Results

Q3

($ in millions, except EPS) 2023 2022 % Change
Reported Sales $21,351 $19,996 6.8%
Net Earnings $4,309 $4,310 0.0%
EPS (diluted) $1.69 $1.62 4.3%

Q3

Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change

Operational Sales 6.4%
Adjusted Operational Sales 4.9%
Adjusted Net Earnings $6,777 $5,938 14.1%
Adjusted EPS (diluted) $2.66 $2.23 19.3%

Regional Sales Results

Q3 % Change
($ in Millions) 2023 2022 Reported Operational Currency Adjusted Operational
U.S. $11,996 $10,794 11.1% 11.1 – 8.9
International $9,355 $9,202 1.6% 0.7 0.9 0.3
Worldwide $21,351 $19,996 6.8% 6.4 0.4 4.9

Segment Sales Results

Q3 % Change
($ in Millions) 2023 2022 Reported Operational Currency Adjusted Operational
Innovative Medicine $13,893 $13,214 5.1% 4.3 0.8 4.4
MedTech $7,458 $6,782 10.0% 10.4 0.4 6.0
Worldwide $21,351 $19,996 6.8% 6.4 0.4 4.9

关于 CareFix

CareFix是一家专业从事骨科医疗器械设计的国家高新技术企业, 生产, 销售和服务. 成立于 2009, 我们致力于儿科植入物,脚 & 脚踝植入物,外固定和脊柱植入物. 欢迎来我厂参观,距上海虹桥机场约半小时车程.